Search | Clinical Trials Finder

Conditions: Influenza
Interventions: H5N1 pISV; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A, GSK Biologicals' investigational vaccine GSK2340273A, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 4
States / cities: Anaheim, California • Stockbridge, Georgia • Lenexa, Kansas + 1 more

Conditions: Healthy
Interventions: VGX-3400X; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Overland Park, Kansas • Rockville, Maryland

Conditions: Influenza, Human
Interventions: FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3, AS03B, AS03A, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 833 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Stockbridge, Georgia • Meridian, Idaho • Cary, North Carolina + 5 more

Conditions: Avian Influenza
Interventions: aH5N1c, Placebo; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 3,196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 26
States / cities: Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 20 more

Conditions: Influenza
Interventions: AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 245 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more

Conditions: Influenza
Interventions: ASO3 Adjuvant, Influenza A/H5N1 Vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Influenza, Virus Diseases
Interventions: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza A Subtype H5N1 Infection
Interventions: Pandemic Influenza Vaccine, Placebo; Biological
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 19 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Influenza
Interventions: VAX161 [STF2.HA5 H5N1]; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Avian Influenza, Influenza Immunisation
Interventions: Aqueous Cream B.P., Imiquimod, Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: A/Vietnam/H5N1 Influenza Virus
Interventions: 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk); Biological · Other
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more

Conditions: Avian Influenza, Influenza Immunisation
Interventions: A/H7N9, MF59, Phosphate Buffered Saline (PBS) diluent; Biological · Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H5N1), Monovalent Avian Influenza VLP (H5N1); Adjuvant, Saline Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Anaheim, California • Miami, Florida • Pembroke Pines, Florida + 2 more

Conditions: Pandemic Influenza
Interventions: A/H5N1, Placebo; Biological
Lead sponsor: Intercell USA, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 501 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Vallejo, California • Miami, Florida • Kansas City, Kansas + 2 more

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 Anhui 2013/AA ca, Inactivated subvirion H7N9 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 50 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Bird Flu, Influenza
Interventions: Placebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1; Other · Biological
Lead sponsor: Emergent BioSolutions; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Lexington, Kentucky • Kansas City, Missouri • Rochester, New York + 1 more

Conditions: Influenza A Virus, H7N9 Subtype
Interventions: H7N9 A/Anhui/13 ca influenza virus vaccine, Inactivated subvirion H7N9 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Influenza A/H5N1 Vaccine, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years and older
Enrollment: 261 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 4
States / cities: Torrance, California • Rochester, New York • Cincinnati, Ohio + 1 more

Conditions: Avian Influenza
Interventions: MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years to 99 Years
Enrollment: 479 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Influenza (Pandemic)
Interventions: Monovalent Avian Influenza VLP (H7N9), Matrix-M1™ adjuvant, Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 610 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Walnut Creek, California • Miami, Florida • Meridian, Idaho + 2 more

Conditions: Influenza
Interventions: GSK influenza virus H5N1 vaccine 1557484A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Atlanta, Georgia • Bethesda, Maryland • Silver Spring, Maryland

Search by objective public record fields.

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age

H5N1 Mix and Match With AS03

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Single Group Study of the Safety of and Immune Response to a Bird Flu Vaccine (H7N3) in Healthy Adults

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

H5N1 With or Without Topical Aldara in Healthy Adults

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

A/H5N1 Dose Ranging Study With Adjuvant Patch

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

Inactivated Influenza A/H5N1 Vaccine in the Elderly

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant

Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure